C-CAMP Non-Resident Incubation Programme Services

You are here

Home » Innovation & Entrepreneurship » Incubation at C-CAMP » C-CAMP Non-Resident Incubation Programme Services

C-CAMP Non-Resident Incubation Program Services (CNRI)

The model for this programme is designed for startups looking to leverage C-CAMP’s network, expertise, and brand association without committing to full-time physical incubation—giving the flexibility while keeping connected to opportunities-
 
  • Portfolio Recognition: Become part of the C-CAMP portfolio and establish your presence within a vibrant bio-innovation hub. Strengthen your positioning and visibility among investors, industry partners, and other key stakeholders.
  • Ecosystem Access: Tap into C-CAMP’s diverse and expansive ecosystem, including:
  1. Funding and investment programs
  2. Office of Technology Transfer for IP and licensing support
  3. Accelerator and mentorship programs tailored to your startup’s domain
  • Knowledge & Networking: Participate in curated events, workshops, and seminars hosted by C-CAMP. Build valuable connections with experts, peers, mentors, and potential collaborators.
  • Need Based access to Cutting-Edge Infrastructure: Access state-of-the-art labs, advanced technology platforms, and core facilities at C-CAMP—available as needed (as per policy) to support your research and product development journey.
 
C-CAMP’s Non-Resident Incubation model offers a strategic opportunity for startups to align with a recognized life sciences innovation hub. The program allows companies to benefit from institutional association and visibility within the broader scientific and entrepreneurial ecosystem. 
 

Contact us at nri_incubation@ccamp.res.in for more information. 

Start-ups incubated under C-CAMP Non-Resident & International Incubation Programme Scheme

International Incubatees

Clemedi

Clemedi AG is a Swiss medical diagnostic company focusing on antibiotic resistance, established in 2019. Clemedi is a paradigm change.Using a combination of next-generation sequencing and AI for the first time, it produces comprehensive diagnoses at historical speed. This achieves 2 things: reduction in antibiotic misuse and dramatic slowing of antibiotic resistance, the next major human health challenge.

Website: https://clemedi.com/

Indian Non-Resident Incubatees

Abgenics LifeSciences Pvt. Ltd.

Abgenics is spearheading the development of unique antibodies, biologicals, drugs and diagnostics for human diseases based on an intimate understanding of disease biology and patient needs. Their technology is a new class of antimicrobials and companion diagnostics against top six drug resistant microbial pathogens. Called AbTids they are biologicals consisting of a pathogen specific heavy chain antibody derived from camels combined with antimicrobial peptides that are effective in the nanomolar range that will be deployed for accurate diagnostics and therapy of drug resistant superbugs.

Website: https://www.abgenics.in/

Invitreo

Invitreo specializes in materializing deep technology healthcare research through academia-industry collaboration.They identify the feasibility of the research in terms of its implications in healthcare and work towards materializing it into a commercially viable technology. They are currently working on longer-term animal trials & commercialisation of a Bioartificial Pancreas, developed by IIT Bombay for Type 1 Diabetes treatment. A Bioartificial Pancreas (BAP) contains pancreatic islets (allogeneic or xenogeneic) or differentiated islets encapsulated within a synthetic biocompatible semipermeable membrane and fully mimics the behaviour and function of a healthy pancreas Their product uses patented stem cell technology and short term trials have shown reversal of Diabetes for 30 days in mouse models

Website: http://www.invitreo.com/